Research output per year
Research output per year
Personal profile
Research interests
My research is focused on pre-clinical studies and early phase clinical trials evaluating molecular therapeutic agents, including IGF-IR antibody and Chk1 inhibitors, for the treatment of breast cancer. Breast cancer cell lines and xenograft models as well as patients’ specimens are used to evaluate the mechanisms of action of these agents and to develop potential predictors of treatment response. A multi-center phase I/II study of IMC-A12 (ImClone Inc.), an IGF-IR antibody, in combination with temsirolimus in patients with metastatic breast cancer has been approved by NCI/CTEP to evaluate the efficacy and tolerability for the combined targeting of IGF-IR and mTOR. In collaboration with Drs. Helen Piwnica-Worms and Paula Fracasso, we are conducting an exploratory study of UCN-01, a Chk1 inhibitor, in combination with irinotecan in patients with triple negative breast cancer (negative for estrogen receptor, progesterone receptor and HER2 overexpression).
Clinical interests
Cancer, breast cancer
Fingerprint
Dive into the research topics where Cynthia Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling
Gerratana, L., Davis, A. A., Foffano, L., Reduzzi, C., Rossi, T., Medford, A., Clifton, K., Shah, A. N., Bucheit, L., Velimirovic, M., Bandini, S., Dai, C. S., Wehbe, F., Gradishar, W. J., Behdad, A., Ulivi, P., Ma, C. X., Puglisi, F., Bardia, A. & Cristofanilli, M., Jan 28 2025, In: Cancer Letters. 609, 217325.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach
Xi, J., Ma, C. X. & O’Shaughnessy, J., Nov 1 2024, In: JCO Oncology Practice. 20, 11, p. 1460-1470 11 p.Research output: Contribution to journal › Review article › peer-review
1 Scopus citations -
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages
Iglesia, M. D., Jayasinghe, R. G., Chen, S., Terekhanova, N. V., Herndon, J. M., Storrs, E., Karpova, A., Zhou, D. C., Naser Al Deen, N., Shinkle, A. T., Lu, R. J. H., Caravan, W., Houston, A., Zhao, Y., Sato, K., Lal, P., Street, C., Martins Rodrigues, F., Southard-Smith, A. N. & Targino da Costa, A. L. N. & 40 others, , Nov 2024, In: Nature Cancer. 5, 11, p. 1713-1736 24 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Endocrine-Sensitive Disease Rate in Postmenopausal Patients with Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
Ma, C. X., Suman, V. J., Sanati, S., Vij, K., Anurag, M., Leitch, A. M., Unzeitig, G. W., Hoog, J., Fernandez-Martinez, A., Fan, C., Gibbs, R. A., Watson, M. A., Dockter, T. J., Hahn, O., Guenther, J. M., Caudle, A., Crouch, E., Tiersten, A., Mita, M. & Razaq, W. & 10 others, , Mar 21 2024, In: JAMA oncology. 10, 3, p. 362-371 10 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models
Guo, Z., Luo, J., Jay Mashl, R., Hoog, J., Maiti, P., Fettig, N., Davies, S. R., Aft, R., Held, J. M., Govindan, R., Ding, L., Li, S., von Morze, C., Wulf, G. M., Shoghi, K. I. & Ma, C. X., Jun 2024, In: Cancer research communications. 4, 6, p. 1430-1440 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations